Corporate fact sheet
Founded
1991
About Corline®
Corline® provides innovative surface technology solutions that significantly improve medical devices, implants and biological tissue for transplantation, adding and enabling biocompatility and pro-healing functions. Some of the world’s largest Medical Device and Regenerative Medicine providers use Corline’s technology CHS™ for critical clinical products.
About CHSâ„¢
CHS™ is a heparin based, single-point attached™ surface modification technology that renders excellent blood- and biocompatibility, and pro-healing functionality. It can be used on a diverse range of artificial materials such as various steel and metal alloys, polymers (ePTFE, PU, PE, etc.) and can even be attached to biological surfaces such as living cells and tissue, without compromising their viability. By using CHS™, the aim for device and health care providers is less blood clotting and inflammation problems for implants, and a more rapid patient recovery after cell and tissue transplantation.
URL
Senior Management Team
Henrik Nittmar, Chief Executive Officer
Kurt Jansson, Chief Operating Officer
Rolf Larsson, Chief Scientific Officer
Board of Directors
Corline’s Board of Directors and senior management team is comprised of extraordinary individuals who bring profound healthcare industry and general business expertise to the company.
Lars Sunnanväder, Chairman of the Board
Adam Dahlberg, Board member
Ownership
Corline® is a privately held company.
Headquarters
Uppsala, Sweden.
